Abstract:

Good response to neoadjuvant chemotherapy is a favorable prognostic factor in patients with breast cancer. Early response evaluation might spare unnecessary chemotherapy in bad responders. Clinically mammography and ultrasound are used to evaluate response to treatment while being bac predictors of early response. MRI is getting wider acceptance but still lacks necessary accuracy to the absence of functional evaluation. Thus novel methods are being evaluated in early response prediction. Diffusion-weighted MRI, MR-spectroscopy, mammoscintigraphy PET as well as diffusion optic tomography are discussed in the review as potential ways to improve early prediction of response in breast cancer patients undergoing neoadjuvant chemotherapy.

References

1.     Davydov M.I., Aksel' E.M. Statistika zlokachestvennyh novoobrazovanij v Rossii i stranah SNG v 2012 g [Statistics of malignancies in Russian Federation and the CIS countries in 2012.]. Moskva, 2014;63-64 [In Russ].

2.     Montagna E., Bagnardi V., Rotmensz N. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Res Treat. 2010;124(3):689-99.

3.     Bonnefoi H., Litiere S., Piccart M. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Ann Oncol. 2014 Jun;25(6):1128-36.

4.     Semiglazov V.F., Paltuev R.M., Semiglazova TJu. i dr. Klinicheskie rekomendacii po diagnostike i lecheniju raka molochnoj zhelezy [Clinical guidelines for the diagnosis and treatment of breast cancer.]. SPb.: ABS-press. 2013; 234 [In Russ].

5.     Schmitt E.L., Threatt B.A. Effective breast cancer detection with filmscreen mammography. Canad. Ass. Radiol. 1985;36(4):303-307.

6.     Mistry K.A., Thakur M.H., Kembhavi S.A. The effect of chemotherapy on the mammographic appearance of breast cancer and correlation with histopathology. Brit. J. Radiol. 2016; 89:1057-1063.

7.     Helvie M.A., Joynt L.K., Cody R.L. et al. Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy. Radiology. 1996;198:327-332.

8.    Komjahov A.V.. Ocenka jeffektivnosti neoad’juvantnoj sistemnoj terapii raka molochnoj zhelezy s pomoshhju magnitno-rezonansnoj tomografii i sonografii [Evaluation of the effectiveness of neoadjuvant systemic therapy for breast cancer using magnetic resonance imaging and sonography.]. Avtoreferat. Diss. kand. med. nauk SPb. 2016; 13-15 [In Russ].

9.    Gazhonova V.E., Efremova M.P., Dorohova E.A. Sovremennye metody neinvazivnoj luchevoj diagnostiki raka molochnoj zhelezy [Modern non-invasive methods of radiation diagnosis of breast cancer.]. RMZh. 2016;5:321-324 [In Russ].

10.  Meladze N.V., Ternovoj S.K., Abduraimov A.B. MR-spektroskopija v differencial'noj diagnostike uzlovyh obrazovanij molochnyh zhelez[MR spectroscopy in the differential diagnosis of nodular breast cancer.]. Bjulleten’ sibirskoj mediciny. 2012;5:78-79 [ In Russ].

11.   Semiglazov V.F., Semiglazov V.V., Krivorot'ko P.V. i dr. Rukovodstvo po lecheniju rannego raka molochnoj zhelezy [Guidelines for early breast cancer therapy.]. SPb. 2016; 12-13 [In Russ].

12.   Marinovich M.L., Macaskill P., Irwig L. et al. Metaanalysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy. Br. J. Cancer. 2013;109:1528-1536.

13.   Meladze N.V. Rol' Mr-spektroskopii v kompleksnoj diagnostiki raka molochnoj zhelezy [MR spectroscopy in the complex diagnosis of breast cancer]. Avtoreferat. Diss. kand. med. nauk. M. 2014;78-79 [In Russ].

14.   Danishad K.K., Sharma U., Sah R.G., et al. Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging. NMR Biomed. 2010;23(3):233-41.

15.   Jonathan K.P, Begley L., Thomas W. In vivo proton magnetic resonance spectroscopy of breast cancer: a review of the literature. Breast Cancer Research. 2012; 14:207.

16.   Bammer R. Basic principles of diffusion-weighted imaging. Eur Radiol. 2003;45:169-184.

17.   Kwee T., Takahara T., Ochiai R. et al. Whole-body diffusion weighted magnetic resonance imaging. Eur Radiol. 2009;70: 409-417.

18.   Smirnova N.A., Nazarov A.A., Del'gadil'o-Kuznecov L.Je. Radionuklidnye metody v diagnostike i lechenii raka molochnoj zhelezy [Radionuclide methods in the diagnosis and treatment of breast cancer.]. Vestnik RUDN. 2005;(29)1: 45-50 [In Russ].

19.  Brjanceva Zh.V. Avtoreferat. Diss. kand. med. nauk. Rol’ mammoscintigrafii v ocenke jeffektivnosti neoad’juvantnogo lechenija raka molochnoj zhelezy [Mammoscintigraphy role in assessing the effectiveness of neoadjuvant treatment of breast cancer.]. SPb. 2015;3-4 [In Russ].

20.   Qiufang Liu, Chen Wang, Panli Li. The Role of 18F- FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis. Biomed Res Int. 2016;2016:10.

21.   Tromberg B.J., Zhang Z., Leproux A. Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging. Сancer Research. 2016;5933.

22.   Baek H.M., Chen J.H, Nie K. Predicting Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer by Using MR Imaging and Quantitative 1H MR Spectroscopy. Radiology. 2009 Jun; 251(3):653-662.

23.   Bufi E., Belli P, Matteo M. Hypervascularity Predicts Complete Pathologic Response to Chemotherapy and Late Outcomes in Breast Cancer. Clinical Breast Cancer. 2016; Jun 23. pii: S1526-8209(16)30162-8.

24.   Hylton N.M., Constantine A., Gatsonis M. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology. 2016; Apr; 279(1):44-55.

25.   Schaefgen B., Mati M., Sinn H. Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response? Annals of Surgical Oncology. 2016;23(3):789-795.

26.   Cho N., Im S.A., Kang K.W. Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel (1)H-magnetic resonance spectroscopy and (18)F-fluorodeoxyglucose positron emission tomography. Eur Radiol. 2016; 26(7):2279-90.

27.   Bufi E., Belli P., Costantini M. Role of the Apparent Diffusion Coefficient in the Prediction of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer. Clin Breast Cancer. 2015 0ct;15(5):370-80.

28.   Leong K.M., Lau P., Ramadan S. Utilisation of MR spectroscopy and diffusion weighted imaging in predicting and monitoring of breast cancer response to chemotherapy. J Med Imaging Radiat Oncol. 2015 Jun;59(3):268-77.

29.   Novikov S.N., Kanaev S.V., Petr K.V. Technetium-99m methoxyisobutylisonitrile scintimammography for monitoring and early prediction of breast cancer response to neoadjuvant chemotherapy. Nucl Med Commun. 2015 Aug; 36(8):795-801.

30.   Trehan R., Seam R.K., Gupta M.K. Role of scintimammography in assessing the response of neoadjuvant chemotherapy in locally advanced breast cancer. World J Nucl Med. 2014 Sep;13(3):163-9.

31.   Schaafsma B.E., van de Giessen M., Charehbili A. Optical mammography using diffuse optical spectroscopy for monitoring tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer. Clin Cancer Res. 2015 Feb; 21(3):5